LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 111 (6), 851-857
- https://doi.org/10.1007/s12185-020-02844-7
Abstract
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) represent a promising treatment option for EBV-associated post-transplantation lymphoproliferative disorders (PTLD). However, production of EBV-CTLs is often complicated and expensive. In the present study, we sought to establish an easy-to-use and economical production protocol for EBV-CTLs. EBV-CTLs were generated using latent membrane protein 1 (LMP1) peptides based on a modified generation protocol of cytokine-induced killer (CIK) cells. After 2-week culture, cells were well expanded (median total cell number: 9.82 x 10(9); median expansion fold: 107.8) and the median EBV LMP1-specific CD8(+) T cell number was 8.94 x 10(8) (median frequency: 6.7%). However, the EBV-CTL products, unlike CIK cells, did not exhibit NK-like anti-tumor activity. Furthermore, the clinical efficacy of EBV-CTLs was demonstrated with a successful treatment of PTLD on a compassionate use basis in a patient following haploidentical hematopoietic stem cell transplantation. This study indicates the safety and efficacy of EBV LMP1-specific CTLs generated based on a modified generation protocol of CIK cells. Further investigation in a well-designed clinical study is warranted.Keywords
Funding Information
- Young Scholar Program of The First Affiliated Hospital of Anhui Medical University (2019kj20)
- Provincial Natural Science Research Project of Colleges and Universities in Anhui Province (KJ2017A834)
This publication has 18 references indexed in Scilit:
- First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell TransplantationClinical Infectious Diseases, 2020
- Post-Transplantation Lymphoproliferative Disorders in AdultsNew England Journal of Medicine, 2018
- Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell TransplantationJournal of Clinical Oncology, 2017
- Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for CytomegalovirusThe Journal of Infectious Diseases, 2017
- Epstein‐Barr virus‐specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinomaCancer, 2017
- Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesHaematologica, 2016
- The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of careCytotherapy, 2014
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantationBlood, 2013
- Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationClinical Infectious Diseases, 2013
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's DiseaseThe Journal of Experimental Medicine, 2004